Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01308762 | A Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 in Adult Melanoma Cancer Patients | completed | Phase 1 | 19 | Immodulon Therapeutics LtdINDUSTRY | 1 | Dec 6, 2012 | clinicaltrials |
| NCT00835419 | Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression(ENVER) | completed | Phase 2 | 12 | Piramal Enterprises LimitedINDUSTRY | 3 | Dec 4, 2012 |
| NCT00324623 | Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma | completed | Phase 1 | 8 | Prof. Serge LeyvrazOTHER | 1 | Nov 20, 2012 | clinicaltrials |
| NCT00328861 | Natural Killer Cells Plus IL-2 Following Chemotherapy to Treat Advanced Melanoma or Kidney Cancer | completed | Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Nov 5, 2012 | clinicaltrials |
| NCT00924001 | Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma | terminated | Phase 1 / Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Oct 25, 2012 | clinicaltrials |
| NCT00059475 | Peptide Vaccination for Patients at High Risk for Recurrent Melanoma | completed | Phase 2 | 138 | National Cancer Institute (NCI)NIH | 1 | Oct 23, 2012 | clinicaltrials |
| NCT00273910 | Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk Melanoma | completed | Phase 2 | 104 | National Cancer Institute (NCI)NIH | 1 | Oct 19, 2012 | clinicaltrials |
| NCT00314106 | Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma | completed | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 1 | Oct 18, 2012 | clinicaltrials |
| NCT00492440 | Interleukin-7 in Treating Patients With Metastatic Melanoma or Locally Advanced or Metastatic Kidney Cancer | terminated | Phase 1 | 9 | Cytheris SAINDUSTRY | 1 | Oct 18, 2012 | clinicaltrials |
| NCT00862914 | Immunohistochemical Expression Patterns of microRNA Processing Enzyme Dicer in Cutaneous Malignant Melanoma, Benign and Dysplastic Melanocytic Naevi | completed | — | 30 | Ruhr University of BochumOTHER | 1 | Oct 16, 2012 | clinicaltrials |
| NCT01444560 | miRNA Machinery in Melanoma, Melanoma Metastases and Benign Melanocytic Naevi | completed | — | 21 | Ruhr University of BochumOTHER | 1 | Oct 16, 2012 | clinicaltrials |
| NCT01331915 | Safety and Toxicity Study of Vaccination for Advanced Metastatic Melanoma Patients(THERAVAC) | unknown | Phase 1 / Phase 2 | 23 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Oct 10, 2012 | clinicaltrials |
| NCT00785369 | In Vivo Confocal Microscopy for Pigmented Lesion Diagnosis | completed | N/A | 441 | Lucid, Inc.INDUSTRY | 1 | Oct 3, 2012 | clinicaltrials |
| NCT00512798 | Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma | terminated | Phase 1 / Phase 2 | 47 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Oct 2, 2012 | clinicaltrials |
| NCT01013623 | Stage IV Surgery Versus Best Medical Therapy(STG4SURG) | terminated | Phase 3 | 12 | Saint John's Cancer InstituteOTHER | 5 | Sep 26, 2012 | clinicaltrials |
| NCT00005615 | Post-Operative Adjuvant Radiotherapy With Concurrent Interferon-Alfa | completed | Phase 1 / Phase 2 | 24 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 25, 2012 | clinicaltrials |
| NCT00020839 | Temozolomide With or Without Radiation Therapy to the Brain in Treating Patients With Stage IV Melanoma That Is Metastatic to the Brain | terminated | Phase 3 | 23 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 11 | Sep 24, 2012 | clinicaltrials |
| NCT00036816 | Vaccine Therapy in Treating Patients With Melanoma of the Eye | terminated | Phase 3 | 13 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 2 | Sep 24, 2012 | clinicaltrials |
| NCT00110123 | Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma | terminated | Phase 3 | 171 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 4 | Sep 24, 2012 | clinicaltrials |
| NCT00798629 | Adenovirus CCL-21 Transduced MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured | completed | Phase 1 | 13 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 24, 2012 | clinicaltrials |
| NCT00039000 | Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma | completed | Phase 3 | 350 | Agenus Inc.INDUSTRY | 9 | Sep 7, 2012 | clinicaltrials |
| NCT01677975 | The Value of Preoperative Dynamic Lymphscintigraphy and Ultrasoundscanning, Eventually With FNA, for Identification of Malignant Sentinel Node(s) in Patients With Melanoma | unknown | N/A | — | Rigshospitalet, DenmarkOTHER | 1 | Sep 3, 2012 | clinicaltrials |
| NCT00003828 | S9804: Vinorelbine in Treating Patients With Stage IV Melanoma | completed | Phase 2 | 24 | SWOG Cancer Research NetworkNETWORK | 1 | Aug 22, 2012 | clinicaltrials |
| NCT00104988 | S0508: Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery | completed | Phase 2 | 64 | SWOG Cancer Research NetworkNETWORK | 1 | Aug 22, 2012 | clinicaltrials |
| NCT00062933 | A Phase II Study of Isolated Hepatic Perfusion (IHP) in Patients With Ocular Melanoma | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2012 | clinicaltrials |
| NCT01294735 | Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1) | completed | Phase 1 | 19 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 15, 2012 | clinicaltrials |
| NCT00506311 | Evaluating the Use of Fibrin Tissue Adhesive in Melanoma Patients | completed | N/A | 53 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 2, 2012 | clinicaltrials |
| NCT00527761 | Taxotere/Temodar/Cisplatin Study in Melanoma Patients | completed | Phase 1 | 23 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2012 | clinicaltrials |
| NCT00014625 | E7070 in Treating Patients With Stage IV Melanoma | completed | Phase 2 | 28 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Jul 24, 2012 | clinicaltrials |
| NCT00085059 | Boron Neutron Capture Therapy Using Boronophenylalanine-Fructose Complex in Treating Patients With Metastatic Melanoma | terminated | Phase 2 | 4 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Jul 18, 2012 | clinicaltrials |
| NCT00003989 | ISIS 3521 in Treating Patients With Advanced, Unresectable, or Metastatic Non-small Cell Lung Cancer or Unresectable or Metastatic Melanoma | completed | Phase 2 | 50 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Jul 11, 2012 | clinicaltrials |
| NCT00023647 | Vaccine Therapy in Treating Patients With Stage IV Melanoma | completed | Phase 1 | 26 | Mannkind CorporationINDUSTRY | 1 | Jul 10, 2012 | clinicaltrials |
| NCT00002669 | Combination Chemotherapy, Interferon Alfa, and Interleukin-2 in Treating Patients With Metastatic Melanoma | completed | Phase 2 | 90 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Jul 2, 2012 | clinicaltrials |
| NCT00257205 | CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy | completed | Phase 3 | 655 | AstraZenecaINDUSTRY | 21 | Jul 2, 2012 | clinicaltrials |
| NCT00094107 | Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma | completed | Phase 2 | 32 | PfizerINDUSTRY | 2 | Jun 26, 2012 | clinicaltrials |
| NCT00077532 | Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma | completed | Phase 2 | 179 | National Institutes of Health Clinical Center (CC)NIH | 1 | Jun 22, 2012 | clinicaltrials |
| NCT00085462 | Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic Melanoma | completed | Phase 1 | 61 | National Institutes of Health Clinical Center (CC)NIH | 1 | Jun 22, 2012 | clinicaltrials |
| NCT01161888 | Effect of Topical Imiquimod on Lentigo Maligna(LIMIT-1) | completed | Phase 4 | 30 | Jerry MarsdenOTHER | 1 | Jun 20, 2012 | clinicaltrials |
| NCT01620749 | Of 18F MEL050 Using PET/CT in Metastatic Melanoma(MEL050) | unknown | Early Phase 1 | 12 | Cooperative Research Centre for Biomedical Imaging DevelopmentOTHER | 1 | Jun 15, 2012 | clinicaltrials |
| NCT00080353 | Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma | completed | Phase 2 | 58 | National Cancer Institute (NCI)NIH | 1 | Jun 14, 2012 | clinicaltrials |
| NCT00295958 | LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By Surgery | completed | Phase 2 | 26 | National Institutes of Health Clinical Center (CC)NIH | 1 | Jun 14, 2012 | clinicaltrials |
| NCT00846833 | Haploidentical NK Cell Infusion in Malignant Melanoma | completed | Phase 1 / Phase 2 | 12 | Seoul National University HospitalOTHER | 1 | Jun 8, 2012 | clinicaltrials |
| NCT00254579 | Study of CP-675,206 in Refractory Melanoma | completed | Phase 2 | 251 | AstraZenecaINDUSTRY | 9 | Jun 7, 2012 | clinicaltrials |
| NCT00281541 | A Study for the Treatment of Unresectable Stage III or Metastatic Stage IV Melanoma | completed | Phase 2 | 29 | Astellas Pharma IncINDUSTRY | 1 | Jun 7, 2012 | clinicaltrials |
| NCT01614301 | Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial in Patients With Advanced Melanoma | unknown | Phase 1 / Phase 2 | 136 | University of RegensburgOTHER | 1 | Jun 7, 2012 | clinicaltrials |
| NCT00086489 | CP-675,206 In Patients With Advanced Melanoma | completed | Phase 2 | 118 | AstraZenecaINDUSTRY | 1 | Jun 6, 2012 | clinicaltrials |
| NCT00431275 | Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody | completed | Phase 1 | 85 | AstraZenecaINDUSTRY | 1 | Jun 6, 2012 | clinicaltrials |
| NCT00585000 | A Study To Assess The Safety Of Administering CP-675,206 As A One Hour Infusion In Patients With Surgically Incurable Advanced Melanoma | terminated | Phase 1 | 49 | AstraZenecaINDUSTRY | 1 | Jun 6, 2012 | clinicaltrials |
| NCT01026051 | Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma | terminated | Phase 2 | 5 | Mannkind CorporationINDUSTRY | 1 | May 15, 2012 | clinicaltrials |
| NCT00412425 | Palonosetron for Prevention of Biochemotherapy Induced Nausea and Vomiting | completed | Phase 1 / Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 4, 2012 | clinicaltrials |
Data updated 23 days agoSource updated Dec 6, 2012source: clinicaltrials